Literature DB >> 17335389

Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene.

Martin Reuter1, Ulrich Ott, Dieter Vaitl, Jürgen Hennig.   

Abstract

Current models of attention describe attention not as a homogenous entity but as a set of neural networks whose measurement yields a set of three endophenotypes-alerting, orienting, and executive control. Previous findings revealed different neuroanatomical regions for these subsystems, and data from twin studies indicate differences in their heritability. The present study investigated the molecular genetic basis of attention in a sample of 100 healthy subjects. Attention performance was assessed with the attention network test that distinguishes alerting, orienting, and executive control (conflict) using a simple reaction time paradigm with different cues and congruent and incongruent flankers. Two gene loci on candidate genes for cognitive functioning, the functional catechol-O-methyltransferase (COMT) VAL158MET and the tryptophan hydroxylase 2 (TPH2) -703 G/T promoter polymorphism, were tested for possible associations with attention. COMT is involved in the catabolism of dopamine, and TPH is the rate-limiting enzyme for serotonin synthesis. Results showed no effect of the COMT polymorphism on attention performance. However, the TT genotype of TPH2 -03 G/T was significantly associated with more errors (a possible indicator of impaired impulse control; p = .001) and with decreased performance in executive control (p = .001). This single-nucleotide polymorphism on the TPH2 gene explained more than 10% of the variance in both indicators of attention stressing the role of the serotonergic system for cognitive functions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335389     DOI: 10.1162/jocn.2007.19.3.401

Source DB:  PubMed          Journal:  J Cogn Neurosci        ISSN: 0898-929X            Impact factor:   3.225


  22 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  [In memory of Lev L'vovich Kiselev].

Authors:  A A Bogdanov; V G Debabov
Journal:  Mol Biol (Mosk)       Date:  2008 Sep-Oct

Review 3.  Stress, genes and the biology of suicidal behavior.

Authors:  Dianne Currier; J John Mann
Journal:  Psychiatr Clin North Am       Date:  2008-06

4.  Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2013-02-19       Impact factor: 5.858

5.  Working memory and parent-rated components of attention in middle childhood: a behavioral genetic study.

Authors:  Zhe Wang; Kirby Deater-Deckard; Laurie Cutting; Lee A Thompson; Stephen A Petrill
Journal:  Behav Genet       Date:  2011-09-27       Impact factor: 2.805

6.  The developing brain in a multitasking world.

Authors:  Mary K Rothbart; Michael I Posner
Journal:  Dev Rev       Date:  2015-03-01

Review 7.  Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-03       Impact factor: 3.568

8.  Developing Attention: Behavioral and Brain Mechanisms.

Authors:  Michael I Posner; Mary K Rothbart; Brad E Sheese; Pascale Voelker
Journal:  Adv Neurosci (Hindawi)       Date:  2014-05-01

Review 9.  The genetics of anxiety-related negative valence system traits.

Authors:  Jeanne E Savage; Chelsea Sawyers; Roxann Roberson-Nay; John M Hettema
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-05-19       Impact factor: 3.568

10.  Gender moderates the association between 5-HTTLPR and decision-making under ambiguity but not under risk.

Authors:  Scott F Stoltenberg; Joanna M Vandever
Journal:  Neuropharmacology       Date:  2009-09-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.